ADAPTIVE BIOTECHNOLOGIES CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $12.76 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $12.76, a 47.51% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $8.65, a 50.71% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $17.55, a 26.97% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $24.03, a 17.14% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $8.80, a 25.30% decline from fiscal 2024.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $11.78, a 30.99% decline from fiscal 2023.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $17.07, a 40.19% decline from fiscal 2022.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $28.54, a 10.19% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.76 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $12.76 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | $8.80 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $8.79 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $8.77 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | $8.65 10-Q · filed 2025-05-01 | |||
| 2024-12-31 | $11.78 10-K · filed 2025-03-03 | |||
| 2024-09-30 | $11.69 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $11.57 10-Q · filed 2024-08-01 | |||
| 2024-03-31 | $17.55 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $17.07 10-K · filed 2024-02-29 | |||
| 2023-09-30 | $16.99 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $17.43 10-Q · filed 2023-08-02 | |||
| 2023-03-31 | $24.03 10-Q · filed 2023-05-03 | |||
| 2022-12-31 | $28.54 10-K · filed 2023-02-14 | |||
| 2022-09-30 | $28.64 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $29.13 10-Q · filed 2022-08-03 | |||
| 2022-03-31 | $29.00 10-Q · filed 2022-05-04 | |||
| 2021-12-31 | $25.90 10-K · filed 2022-02-15 | |||
| 2021-09-30 | $24.48 10-Q · filed 2021-11-03 | |||
| 2021-06-30 | $21.80 10-Q · filed 2021-08-04 | |||
| 2021-03-31 | $15.47 10-Q · filed 2021-05-05 | |||
| 2020-12-31 | $16.17 10-K · filed 2021-02-24 | |||
| 2020-09-30 | $14.19 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | $15.77 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | $8.63 10-Q · filed 2020-05-12 | |||
| 2019-12-31 | $6.24 10-K · filed 2020-02-26 | |||
| 2019-09-30 | $6.08 10-Q · filed 2019-11-12 | |||
| 2018-12-31 | $4.86 10-K · filed 2020-02-26 | |||
| 2017-12-31 | $5.51 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |